Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Personalized Care

Data-Driven Precision Medicine:
A Must-Have for the Next-Generation of Personalized Care
Alyssa Antonopoulos, Precision Medicine, Associate Director
Adem Albayrak, VP of Technology, Life Sciences Business
Sadiqa Mahmood, Medical Affairs, SVP
Elia Stupka, PhD, SVP and General Manager, Life Sciences Business

© 2020 Health Catalyst
Proprietary. Feel free to share but we would appreciate a Health Catalyst citation.
Data-Driven Precision Medicine
Healthcare is moving towards a highly
individual model of precision medicine,
which aims to deliver “the right drug for the
right patient at the right time”—particularly
for cancer treatment.
With this individualized approach, targeted
therapies are an increasingly prominent
component of care.

For clinicians, academics, and pharma and
biotech researchers and regulators, the
biggest challenge in meeting precision
medicine goals and optimally leveraging
targeted therapy pertains to data—
establishing the ability to collect and share
data for patient care, research, drug
development, and reimbursement.
Capturing and reporting on relevant
real-world data (RWD) is a top asset.

This report examines the gaps in clinical care,
research, and drug development inherent with
a lack of combined molecular and clinical data.
It also considers how accessible data, products
to use that data (e.g., the Health Catalyst®
Precision Medicine Portfolio [PMP], Figure 1),
and a core data management system.
In this case, the Health Catalyst® Molecular
and Clinical DOS Marts™ can help clinicians,
academics, pharma, and biotech researchers
and regulators advance the precision medicine
goals of highly individualized treatment.

Precision Medicine Portfolio (PMP)
Figure 1: The PMP

The Right Tools for Data-Driven Precision Medicine
The PMP is a suite of products fully integrated
into the Health Catalyst Data Operating System
(DOS™) and includes applications that
manage and analyze clinical, research, and
operational data—including molecular data.”
The Molecular DOS Mart (Figure 2),
fundamental to the portfolio, is a data trans-
formation and management model that
incorporates data from disparate sources,
including genomics, transcriptomics, and
even molecular pathology labs (e.g.,
polymerase chain reaction [PCR] and
ImmunoHistoChemistry [IHC] testing data).

Figure 2: The Molecular DOS Mart

The extended Population Builder™:
Stratification Module incorporates data from
the Molecular DOS Mart to complement rich
clinical data for cohort building and
aggregate querying for researchers in
academia, pharma, and biotech.

Gaps in Clinical Care, Research, and Drug
Development—An Improvement Opportunity
Research indicates that wait times vary
between identification of a genetic mutation
and receipt of the appropriate targeted therapy.
This gap between molecular testing and
targeted therapy raises the question of
whether patients are receiving the timeliest
treatment possible.

By better understanding the interval between
testing and prescription or administration and
influential factors, health systems and life
sciences organizations can move towards
treating patients with care that uniquely meets
their needs, with the most optimal timing.

For example, some patients might already be
on a treatment plan (e.g., chemotherapy or
radiation treatment) when they undergo
molecular testing, which may account for the
gap in receipt of the targeted therapy.
Understanding treatment on this operational
level helps care teams and researchers
benchmark processes accordingly so they
can link delays with certain outcomes and, in
some cases, identify instances in which a
longer delay would benefit the patient.

The Molecular DOS Mart uses a comprehensive
schema, harmonizing molecular information from
disparate sources, including lab testing such as
PCR and IHC, as well as next-generation
sequencing (NGS) testing.
The Molecular DOS Mart includes patients’
molecular test data describing the following:
The tested gene.
The variant at the DNA and protein level.
The result.
The result date timestamp (when available).
>
>
>
>

The above information is combined with the
therapy order or administration and the
associated date timestamp from the Clinical
DOS Mart.
Together, they allow assessment of the
number of days between molecular testing
and order or administration of a targeted
therapy for a given biomarker-drug
association

This simplifies assessment of the number of
days between molecular testing and order
or administration of an associated targeted
therapy by hospital, drug, and gene.
The Clinical DOS Mart also enables
filtering by diagnosis, which is relevant
as more therapies become approved in
additional indications.

Three Critical Ways a Precision Medicine Portfolio
Drives More Personalized Care
Using Clinical and Molecular DOS Marts, the PMP
contributes three critical assets to help life sciences
organizations advance precision medicine goals:
1. A Longitudinal Record of the Patient Journey
2. Access to Real-World Evidence
3. More Effective Research Study Design and Patient
Identification for Clinical Trial Recruitment

1: A Longitudinal Record of the Patient Journey
Linked molecular and clinical data enables a
view into the patient journey, called the
patient longitudinal record.
The PMP includes an application that
surfaces an individual patient’s molecular
test results and clinical information,
including diagnoses, medications, and
procedures, as needed—for clinicians
and researchers alike.

1: A Longitudinal Record of the Patient Journey
This information is rarely combined in one
place, but by leveraging the Molecular and
Clinical DOS Marts, Health Catalyst is uniquely
positioned to provide a patient journey application.
Such a tool can help clinicians interpret
genomics data in the context of clinical and
operational data within their workflow while
also providing a researcher- and pharma-facing
view for patients participating in clinical trials.

2: Access to Real-World Evidence
Leveraging both the Molecular and Clinical
DOS Marts sourcing data from the point of
care in real time or minimal lag enables
researchers to answer additional questions
surrounding precision medicine.
Clinicians, academics, and pharma and
biotech researchers can determine the
number of patients on a targeted therapy
who also received molecular testing prior
to or following treatment.

2: Access to Real-World Evidence
Furthermore, the Molecular and Clinical
DOS Marts can answer broader questions
about targeted therapies in the clinical
setting—such as length of time between
approval of a targeted therapy, efficacy of
drugs, and overall adoption of the drug.
The Molecular DOS Mart can provide
clinicians and academic, pharma, and
biotech researchers with longitudinal
molecular data linked with diverse clinical
data and outcomes, enabling biomarker
identification and research.

3: More Effective Research Study Design and Patient Identification
for Clinical Trial Recruitment
Precision medicine clinical trial design must
efficiently and dynamically incorporate genomic
data and assess the value of matching profiled
patients whose tumors harbor unique genomic
alterations to specific clinical trials.

3: More Effective Research Study Design and Patient Identification
for Clinical Trial Recruitment
These demands drive a market need for cohort
design tools based on combined biomarker and
clinical inclusion or exclusion criteria.
With its broad-reaching access to RWD, the Health
Catalyst PMP, powered by combined Molecular and
Clinical DOS Mart, can serve as a singular and
comprehensive source for patient identification.

A Precision Medicine Portfolio Supports a More Robust,
Effective Clinical Trials Process
Realizing the precision medicine goals of
personalized care (treating the right patient
with the right drug at the time) rests heavily
on data.
Academic medical centers, hospitals and
life sciences companies that can have
timely access to molecular and clinical
data and a capable core data management
system will be best positioned to deliver on
the promise of individualized care and
targeted therapies.

For more information:
“This book is a fantastic piece of work”
– Robert Lindeman MD, FAAP, Chief Physician Quality Officer

More about this topic
Link to original article for a more in-depth discussion.
Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Personalized Care
Extended Real-World Data: The Life Science Industry’s Number One Asset
Precision Medicine: Four Trends Make It Possible
John D. Halamka, MD, MS, Professor of Medicine at Harvard Medical School and CIO at Beth Israel Deaconess
Medical Center
A New Era of Personalized Medicine: The Power of Analytics and AI
Heath Catalyst Editors
Healthcare Data: Creating a Learning Healthcare Ecosystem
Bridging the Data and Trust Gaps: Why Health Catalyst Entered the Life Sciences Market
Dale Sanders, Chief Technology Officer

Other Clinical Quality Improvement Resources
Click to read additional information at www.healthcatalyst.com
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In id ante sit amet ante interdum mattis.
Quisque nunc ex, tincidunt nec commodo vel, cursus at tortor. Morbi non viverra turpis. Lorem
ipsum dolor sit amet, consectetur adipiscing elit. Quisque aliquam diam sed tellus vehicula
euismod. Maecenas in ultrices dui. Suspendisse elit lacus, vulputate nec lorem non, egestas
gravida nunc. Curabitur cursus id nulla eget lobortis.Donec elementum diam non pretium
venenatis. Donec massa arcu, ultricies sed tortor non, rhoncus molestie erat. Donec sapien ex,
ullamcorper nec luctus at, consequat at sem. Suspendisse vehicula est a lectus rhoncus, vitae
rutrum libero auctor. Praesent lacinia at neque nec ornare. Nullam sed est lorem. Cras dignissim
varius massa sed maximus. Mauris sit amet blandit ex, dictum aliquam nibh. Aenean sit amet nibh ut enim
malesuada finibus vel at est. Proin hendrerit nisi porttitor lectus elementum lacinia. Cras nec ipsum sagittis,
tristique nibh eget, tempor lectus. Nunc purus massa, ornare nec egestas non, ullamcorper sed sem. Aenean at
feugiat leo, at tincidunt tortor. Mauris vel venenatis arcu, vel gravida lacus. Phasellus ut dictum arcu. Praesent sit
amet nisl ut dolor rutrum congue non at lacus. Curabitur rutrum porta ipsum id semper. Ut non elementum est.
Nam vitae metus eu sem sollicitudin ullamcorper. Fusce feugiat felis tortor, sit amet eleifend velit pellentesque sed.
Donec sem ipsum, tristique at tristique eget, volutpat eget neque. In at dolor eleifend, vulputate magna sit amet,
cursus felis. Integer volutpat pulvinar neque at gravida. Mauris feugiat lacus in lorem finibus.
Alyssa Antonopoulos

Adem Albayrak

Sadiqa Mahmood

Dr. Elia Stupka is the Senior Vice President and General Manager of the Life Sciences business
unit at Health Catalyst and contributes to the overall vision and growth for the company. He is a
visionary leader in digital health with a passion for innovation in health and life sciences and 20
years of experience across industry, academic and clinical settings. In his role leading data
science at Dana-Farber Cancer Institute, one of the world’s leading cancer organizations, Dr.
Stupka brought together research, clinical and operational data to improve patient outcomes and
the discovery of new treatments. He started his career as a member of the first team that
annotated the human genome in Cambridge, U.K., in 1999-2001.
Dr Stupka’s Bio continues here.
Dr. Elia Stupka

Health Catalyst is a mission-driven data warehousing, analytics and outcomes-improvement company
that helps healthcare organizations of all sizes improve clinical, financial, and operational outcomes
needed to improve population health and accountable care. Our proven enterprise data warehouse
(EDW) and analytics platform helps improve quality, add efficiency and lower costs in support of more
than 65 million patients for organizations ranging from the largest US health system to forward-thinking
physician practices.
Health Catalyst was recently named as the leader in the enterprise healthcare BI market in
improvement by KLAS, and has received numerous best-place-to work awards including Modern
Healthcare in 2013, 2014, and 2015, as well as other recognitions such as “Best Place to work for
Millenials, and a “Best Perks for Women.”

Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Personalized Care

Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Personalized Care

Recomendados

Más contenido relacionado

Was ist angesagt?

Was ist angesagt?(20)

Similar a Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Personalized Care

Similar a Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Personalized Care(20)

Más de Health Catalyst

Más de Health Catalyst(20)

Último

Último(20)

Data-Driven Precision Medicine: A Must-Have for the Next-Generation of Personalized Care